Neurolentech

Neurolentech is a pioneering human-only CNS translational platform leveraging patient-derived iPSC neuronal models to evaluate approved drugs and novel combinations for neurodevelopmental disorders such as epilepsy and autism. In light of the FDA’s removal of mandatory animal testing, we are leading the shift toward a human-first “clinical trial in a dish” paradigm — generating regulatory-grade evidence, de-risking CNS trials, and accelerating the path to effective therapies.